<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        78-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GARDIA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DESETHYL CANDESARTAN CILEXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is Gardia. The active ingredient is candesartan cilexetil. This belongs to a group of medicines called angiotensin II receptor antagonists. It works by making your blood vessels relax and widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body.</p><p>This medicine is used for:</p><p>&bull; Treating high blood pressure (hypertension) in adult patients and in children and adolescents aged 6 to under 18 years .</p><p>&bull; Treating adult heart failure patients with reduced heart muscle function, when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used or in addition to ACE inhibitors when symptoms persist despite treatment and mineralocorticoid receptor antagonists (MRA) cannot be used (ACE inhibitors and MRAs are medicines used to treat heart failure).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Gardia </strong></p><p>&bull; If you are allergic to candesartan cilexetil or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; If you are more than 3 months pregnant (it is also better to avoid Gardia in early pregnancy &ndash; see pregnancy section).</p><p>&bull; If you have severe liver disease or biliary obstruction (a problem with the drainage of the bile from the gall bladder).</p><p>&bull; If the patient is a child under 1 year of age.</p><p>&bull; If you are taking a blood pressure lowering medicine containing aliskiren and you have diabetes or impaired kidney function.</p><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Gardia.</p><p>&nbsp;</p><p><strong>Warnings and Precautions </strong></p><p>Talk to your doctor before taking Gardia:</p><p>&bull; If you have heart, liver or kidney problems, or are on dialysis.</p><p>&bull; If you have recently had a kidney transplant.</p><p>&bull; If you are vomiting, have recently had severe vomiting, or have diarrhoea.</p><p>&bull; If you have a disease of the adrenal gland called Conn&rsquo;s syndrome (also called primary hyperaldosteronism).</p><p>&bull; If you have low blood pressure.</p><p>&bull; If you have ever had a stroke.</p><p>&bull; You must tell your doctor if you think you are (or might become) pregnant. Gardia is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p>&bull; If you are taking any of the following medicines used to treat high blood pressure:</p><p>- An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes related kidney problems.</p><p>- Aliskiren.</p><p>&bull; If you are taking an ACE-inhibitor together with a medicine which belongs to the class of medicines known as mineralocorticoid receptors antagonists (MRA). These medicines are for the treatment of heart failure (see &ldquo;Other medicines and Gardia&rdquo;).</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Gardia&rdquo;.</p><p>Your doctor may want to see you more often and do some tests if you have any of these conditions.</p><p>If you are going to have an operation, tell your doctor or dentist that you are taking Gardia. This is because Gardia, when combined with some anaesthetics, may cause a drop in blood pressure.</p><p><strong>Children and adolescents </strong></p><p>Gardia has been studied in children. For more information, talk to your doctor. Gardia must not be given to children under 1 year of age due to the potential risk to the developing kidneys.</p><p><strong>Other medicines and Gardia </strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>Gardia can affect the way some other medicines work and some medicines can have an effect on Gardia. If you are using certain medicines, your doctor may need to do blood tests from time to time.</p><p>In particular, tell your doctor if you are using any of the following medicines as your doctor may need to change your dose and/or take other precautions:</p><p>&bull; Other medicines to help lower your blood pressure, including beta-blockers, diazoxide and ACE inhibitors such as enalapril, captopril, lisinopril or ramipril.</p><p>&bull; Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines to relieve pain and inflammation).</p><p>&bull; Acetylsalicylic acid (if you are taking more than 3 g each day) (medicine to relieve pain and inflammation).</p><p>&bull; Potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood).</p><p>&bull; Heparin (a medicine for thinning the blood).</p><p>&bull; Water tablets (diuretics).</p><p>&bull; Lithium (a medicine for mental health problems).</p><p>&bull; If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Gardia&rdquo; and &ldquo;Warnings and precautions&rdquo;)</p><p>&bull; If you are being treated with an ACE-inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, eplerenone).</p><p>&nbsp;</p><p><strong>Gardia with food and drink and alcohol </strong></p><p>&bull; You can take Gardia with or without food.</p><p>&bull; When you are prescribed Gardia, discuss with your doctor before drinking alcohol. Alcohol may make you feel faint or dizzy.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Pregnancy</p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Gardia before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Gardia. Gardia is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>Breast-feeding</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Gardia is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p><strong>Driving and using machines </strong></p><p>Some people may feel tired or dizzy when taking Gardia. If this happens to you, do not drive or use any tools or machines.</p><p><strong>Gardia contains lactose </strong></p><p>Lactose is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. It is important to keep taking Gardia every day. You can take Gardia with or without food.</p><p>Swallow the tablet with a drink of water.</p><p>Try to take the tablet at the same time each day. This will help you to remember to take it.</p><p>Gardia 16mg and 32mg tablets: The tablet can be divided into equal doses.</p><p>High blood pressure:</p><p>&bull; The recommended dose of Gardia is 8 mg once a day. Your doctor may increase this dose to 16 mg once a day and further up to 32 mg once a day depending on blood pressure response.</p><p>&bull; In some patients, such as those with liver problems, kidney problems or those who recently have lost body fluids, e.g., through vomiting or diarrhoea or by using water tablets, the doctor may prescribe a lower starting dose.</p><p>&bull; Some black patients may have a reduced response to this type of medicine, when given as the only treatment, and these patients may need a higher dose.</p><p>&nbsp;</p><p><strong>Use in children and adolescents with high blood pressure: </strong></p><p>Children 6 to under 18 years of age:</p><p>The recommended starting dose is 4mg once a day.</p><p>For patients weighing less than 50 kg: In some patients whose blood pressure is not adequately controlled, your doctor may decide the dose needs to be increased to a maximum of 8mg once daily.</p><p>For patients weighing 50 kg or more: In some patients whose blood pressure is not adequately controlled, your doctor may decide the dose needs to be increased to 8mg once daily and to 16mg once daily.</p><p>Heart failure in adults:</p><p>&bull; The recommended starting dose of Gardia is 4 mg once a day. Your doctor may increase your dose by doubling the dose at intervals of at least 2 weeks up to 32 mg once a day. Gardia can be taken together with other medicines for heart failure, and your doctor will decide which treatment is suitable for you.</p><p><strong>If you take more Gardia than you should </strong></p><p>If you take more Gardia than prescribed by your doctor, contact a doctor or pharmacist immediately for advice.</p><p><strong>If you forget to take Gardia </strong></p><p>Do not take a double dose to make up for a forgotten tablet. Just take the next dose as normal.</p><p><strong>If you stop taking Gardia </strong></p><p>If you stop taking Gardia, your blood pressure may increase again. Therefore do not stop taking Gardia without first talking to your doctor.</p><p>If you have any further questions on the use of&nbsp;this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. It is important that you are aware of what these side effects may be.</p><p><strong>Stop taking Gardia and seek medical help immediately if you have any of the following allergic reactions: </strong></p><p>&bull; Difficulties in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p>&bull; Swelling of the face, lips, tongue and/or throat, which may cause difficulties in swallowing</p><p>&bull; Severe itching of the skin (with raised lumps)</p><p>&nbsp;</p><p>Gardia may cause a reduction in number of white blood cells. Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. If this happens contact your doctor. Your doctor may occasionally do blood tests to check whether Gardia has had any effect on your blood (agranulocytosis).</p><p>Other possible side effects include:</p><p><strong>Common (affects 1 to 10 users in 100) </strong></p><p>&bull; Feeling dizzy/spinning sensation.</p><p>&bull; Headache.</p><p>&bull; Respiratory infection.</p><p>&bull; Low blood pressure. This may make you feel faint or dizzy.</p><p>&bull; Changes in blood test results:</p><p>- An increased amount of potassium in your blood, especially if you already have kidney problems or heart failure. If this is severe you may notice tiredness, weakness, irregular heart beat or pins and needles.</p><p>&bull; Effects on how your kidneys work, especially if you already have kidney problems or heart failure. In very rare cases, kidney failure may occur.</p><p><strong>Very rare (affects less than 1 user in 10,000) </strong></p><p>&bull; Swelling of the face, lips, tongue and/or throat.</p><p>&bull; A reduction in your red or white blood cells. You may notice tiredness, an infection or a fever.</p><p>&bull; Skin rash, lumpy rash (hives).</p><p>&bull; Itching.</p><p>&bull; Back pain, pain in joints and muscles.</p><p>&bull; Changes in how your liver is working, including inflammation of the liver (hepatitis). You may notice tiredness, yellowing of your skin and the whites of your eyes and flu like symptoms.</p><p>&bull; Cough.</p><p>&bull; Nausea.</p><p>&bull; Changes in blood test results:</p><p>- A reduced amount of sodium in your blood. If this is severe then you may notice weakness, lack of energy, or muscle cramps.</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><p>&bull; Diarrhoea</p><p>In children treated for high blood pressure, side effects appear to be similar to those seen in adults, but they happen more often. Sore throat is a very common side effect in children. Runny nose, fever and increased heart rate are common side effects in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep this medicine out of the sight and reach of children.</p><p>&bull; Do not use this medicine after the expiry date which is stated on the carton label and blister foil after (EXP). The expiry date refers to the last day of that month.</p><p>&bull; Do not store above 30&ordm;C.</p><p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is candesartan cilexetil. Each tablet contains 8 mg or 16 mg of candesartan cilexetil.</p><p>&bull; Hydroxy propyl Cellulose, Lactose Monohydrate, Poly Ethylene Glycol,</p><p>Maize Starch, Ferric Iron Oxide, Calcium Carboxymethyl Cellulose,</p><p>Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gardia 8mg Tablets: Faint pink mottled rounded biconvex tablet embossed with E72 on one side plain on the other.
Gardia 16mg Tablets: Faint pink mottled round scored biconvex tablet embossed with E71 on one side, plain on the other side.
Gardia Tablets are packed in PVC/PVDC/Aluminum blisters, in carton box with a folded leaflet, in pack size of 30 Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>Manufacturer by:</strong></p><p>United Pharmaceutical Mfg. Co. Ltd. for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jun-19
SPM190326

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم الدواء: جارديا المادة الفعالة: كانديزارتان سيلكيزيتيل ينتمي هذا الدواء إلى مجموعة من الأدوية تُسمّى حاصرات مستقبلات الأنجيوتنسين 2. تعمل هذه الأدوية على إرخاء الأوعية الدموية وتوسعتها.&nbsp; يساعد ذلك في خفض ضغط الدم. كما أنه يسهل على القلب ضخ الدم إلى جميع أجزاء الجسم.</p><p dir="RTL">&nbsp;يستخدم هذا الدواء في الآتي:</p><p dir="RTL">&nbsp;علاج ارتفاع ضغط الدم في البالغين والأطفال والمراهقين من سن 6 إلى أقل من 18 سنة.</p><p dir="RTL">&nbsp;علاج فشل القلب في المرضى البالغين الذين يعانون من نقص في وظيفة عضلة القلب، عندما لا يمكن استخدام مثبطات الإنزيم المُحوّل للأنجيوتنسين أو استمرار وجود الأعراض بالرغم من العلاج بمثبطات الإنزيم المُحوّل للأنجيوتنسين أو في الحالات التي لا يمكن فيها استخدام حاصرات مستقبلات الستيرويدات المعدنية القشرية. (يعد كل من مثبطات الإنزيم المُحوّل للأنجيوتنسين وحاصرات مستقبلات الستيرويدات المعدنية القشرية أدوية لعلاج فشل القلب).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;لا تتناول جارديا في الحالات الآتية</strong></p><p dir="RTL">&nbsp;&bull;إذا كانت لديك حساسية مفرطة لمادة كانديزارتان سيلكيزيتيل أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6).</p><p dir="RTL">&bull;إذا كنت سيدة حامل منذ أكثر من 3 أشهر (من الأفضل أيضًا تجنب جارديا في بداية الحمل - يرجى الاطلاع على فقرة الحمل).</p><p dir="RTL">&bull;إذا كنت تعاني من مرض شديد في الكبد أو انسداد في القنوات المرارية (مشكلة في خروج العصارة المرارية من الحوصلة المرارية).</p><p dir="RTL">&bull;إذا كان المريض طفل أقل من عام واحد.</p><p dir="RTL">&bull;إذا كنت تتناول أدوية خافضة لضغط الدم تحتوي على أليسكيرن وأنت تعاني من مرض السكري أو من خلل في وظائف الكلية.</p><p dir="RTL">&nbsp;يجب استشارة الطبيب أو الصيدليّ قبل أخذ هذا الدواء إذا لم تكن متأكدًا مما إذا كان أي منها ينطبق عليك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;التحذيرات والاحتياطات:</strong></p><p dir="RTL">&nbsp;استشر طبيبك قبل تناول هذا الدواء في الحالات الآتية:</p><p dir="RTL">&nbsp;إذا كنت تعاني من مشاكل في القلب أو الكبد أو الكلية، أو إذا كنت تخضع للغسيل الكلوي.</p><p dir="RTL">&nbsp;إذا خضعت مؤخرا لعملية زرع كلية.</p><p dir="RTL">&nbsp;إذا كنت تعاني من قيء أو عانيت مؤخرا من قيء شديد أو إسهال.</p><p dir="RTL">&nbsp;إذا كنت تعاني من مرض في الغدة الكظرية يسمى متلازمة كون (يسمى أيضا فرط الألدوستيرون الأوّلي).</p><p dir="RTL">&nbsp;إذا كنت تعاني من انخفاض ضغط الدم.</p><p dir="RTL">&nbsp;إذا سبق وأصبت بجلطة دماغية.</p><p dir="RTL">&nbsp;يجب إبلاغ الطبيب إذا كنت تعتقدين أنك حامل أو يمكن أن تحملي.&nbsp; لا ينصح بتناول دواء جارديا في بداية الحمل، ويُحذر تناوله بعد مرور الثلاثة أشهر الأولى من الحمل، لأنه يمكن أن يسبب ضررا شديدا إلى الجنين إذا ما تم تناوله في هذه المرحلة (يرجى الاطلاع على فقرة الحمل).</p><p>&nbsp;</p><p dir="RTL">&nbsp;إذا كنت تتناول أيا من الأدوية التالية التي تستخدم في علاج ارتفاع ضغط الدم:</p><p dir="RTL">مثبطات الإنزيم المُحوّل للأنجيوتنسين (على سبيل المثال: إينالابريل، ليزينوبريل، راميبريل) خاصة إذا كنت تعاني من مشاكل في الكلية بسبب مرض السكري.</p><p dir="RTL">&nbsp;أليسكيرن.</p><p dir="RTL">&nbsp;إذ كنت تتناول أحد الأدوية المثبطة للإنزيم المُحوّل للأنجيوتنسين بالتزامن مع تناولك لأدوية تنتمي لمجموعة دوائية تسمى حاصرات مستقبلات الستيرويدات المعدنية القشرية. تستخدم هذه الأدوية لعلاج فشل القلب (يرجى الاطلاع على فقرة تناول أدوية أخرى مع جارديا).</p><p dir="RTL">&nbsp;يمكن أن يفحص الطبيب وظائف الكلى وضغط الدم ومستوى الالكتروليت (مثل البوتاسيوم) في الجسم على فترات زمنية منتظمة.</p><p dir="RTL">&nbsp;يرجى الاطلاع أيضا على المعلومات الموجودة تحت عنوان &quot;لا تتناول جارديا في الحالات الآتية&quot;.</p><p dir="RTL">&nbsp;قد يرغب الطبيب في رؤيتك في كثير من الأحيان وإجراء بعض الاختبارات إذا كان لديك أي من هذه الحالات.</p><p dir="RTL">&nbsp;إذا كنت ستخضع لعملية جراحية، فيجب أن تخير الطبيب أو طبيب الأسنان أنك تتناول جارديا. وذلك لأن جارديا يمكن أن يتسبب في خفض شديد في مستوى ضغط الدم إذا ما تم تناوله مع بعض أدوية التخدير.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الأطفال والمراهقين</strong></p><p dir="RTL">&nbsp;تم دراسة استخدام هذ الدواء في الأطفال. لمزيد من المعلومات، يرجى التوجه إلى الطبيب. يجب تجنب إعطاء هذا الدواء إلى الأطفال الذين تقل أعمارهم عن عام واحد، وذلك لوجود مخاطر محتملة لإصابة الكلية التي لم يكتمل نموها بعد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;تناول أدوية أخرى مع جارديا</strong></p><p dir="RTL">&nbsp;يجب إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر.</p><p dir="RTL">&nbsp; يمكن أن يؤثر هذا الدواء على طريقة عمل بعض الأدوية الأخرى كما أن بعض الأدوية قد تؤثر على فاعلية هذا الدواء.&nbsp; سيحتاج الطبيب لإجراء بعض فحوصات الدم من حين لآخر إذا كنت تتناول بعض الأدوية المعينة.</p><p dir="RTL">&nbsp;وبصورة خاصة؛ فيجب أن تخبر الطبيب إذا كنت تتناول أيًا من الأدوية التالية لأنه قد يحتاج إلى تغيير الجرعة و / أو اتخاذ احتياطات أخرى:</p><p dir="RTL">&nbsp;الأدوية الأخرى التي تساعد في خفض ضغط الدم، بما في ذلك حاصرات مستقبلات بيا وديازوكسيد والأدوية المثبطة للإنزيم المُحوّل للأنجيوتنسين مثل إينالابريل، ليزينوبريل، راميبريل، كابتوبريل.</p><p dir="RTL">الأدوية غير الستيرودية المضادة للالتهابات مثل إيبيبروفين، نابروكزين، دايكلوفينك، سليكوكسيب، إيتوريكوكسيب (الأدوية المسكنة للألم والالتهاب).</p><p dir="RTL">&nbsp;حمض السالسيليك (إذا كنت تتناول منه أكثر من 2 جم في اليوم) (الأدوية المسكنة للألم والالتهاب).</p><p dir="RTL">&nbsp;مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم (الأدوية التي تعمل على زيادة مستوى البتاسيوم في الدم).</p><p dir="RTL">&nbsp;هيبارين (دواء يستخدم في سيولة الدم).</p><p dir="RTL">&nbsp;أقراص المياه (الأدوية المدرة للبول).</p><p dir="RTL">&nbsp;ليثيوم (دواء يستخدم في علاج مشاكل الصحة العقلية).</p><p dir="RTL">&nbsp;إذا كنت تتناول أحد الأدوية المثبطة للإنزيم المُحوّل للأنجيوتنسين أو دواء أليسكيرن (يرجى أيضا الاطلاع على المعلومات الموجودة تحت عنوان &quot;لا تتناول جارديا في الحالات الآتية&quot; و &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&nbsp;إذا كنت تُعالج بأحد الأدوية المثبطة للإنزيم المُحوّل للأنجيوتنسين بالتزامن مع أدوية أخرى لعلاج فشل القلب، والتي تعرف باسم حاصرات مستقبلات الستيرويدات المعدنية القشرية (مثل: سبيرونولاكتون، إيبليريون).</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;تناول جارديا&nbsp; مع الأطعمة والمشروبات والكحوليات</strong></p><p dir="RTL">&nbsp;يمكنك تناول جارديا مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;إذا ما تم وصف هذا الدواء لك، فيجب أن تستشير الطبيب قبل تناول أيا من المشروبات الكحولية. يمكن أن يتسبب شرب المواد الكحولية في الشعور بالإغماء أو الدوار.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;الحمل</p><p dir="RTL">&nbsp;يجب إبلاغ الطبيب إذا كنت تعتقدين أنك حامل أو يمكن أن تحملي. سينصحك الطبيب في الظروف الطبيعية بضرورة التوقف عن تناول هذا الدواء قبل حصول الحمل أو بمجرد المعرفة بوجود الحمل، كما سينصح الطبيب بتناول دوء آخر بدلا من جارديا. لا ينصح بتناول دواء جارديا في بداية الحمل، ويُحذر تناوله بعد مرور الثلاثة أشهر الأولى من الحمل، لأنه يمكن أن يسبب ضررا شديدا في الجنين إذا ما تم تناوله في بعد مرور 3 أشهر من الحمل.</p><p dir="RTL">&nbsp;الرضاعة الطبيعية</p><p dir="RTL">&nbsp;يجب استشارة الطبيب قبل تناول هذا الدواء في حالة السيدات التي تقوم بالرضاعة الطبيعية أو عند بداية الرضاعة الطبيعية. لا يُنصح بتناول جارديا في الأمهات المرضعات، وقد يختار الطبيب دواء آخر لك إذا كنت تريدين الاستمرار في الرضاعة الطبيعية، خاصة إذا كان الطفل لم يزل حديث الولادة أو قد ولد قبل تمام فترة الحمل الطبيعية.</p><p dir="RTL"><strong>&nbsp;القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;قد يشعر بعض الناس بالتعب أو الدوار عند تناول هذا الدواء. وفي حالة حدوث ذلك، فيجب عليك تجنب القيادة أو استخدام أية أدوات أو آلات.</p><p dir="RTL"><strong>&nbsp;يحتوي جارديا على اللاكتوز</strong></p><p dir="RTL">&nbsp;اللاكتوز هو نوع من أنواع السكر. ينبغي استشارة الطبيب قبل تناول هذا الدواء إذا كان قد سبق وأخبرك الطبيب بعدم قدرتك على تحمل بعض أنواع السكر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك تناول هذا الدواء وفقًا لتعليمات الطبيب. يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك. من الضروري أن تحافظ على تناول هذا الدواء يوميا.&nbsp; يمكنك تناول جارديا مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;ابلع القرص باستخدام كوب من الماء.</p><p dir="RTL">&nbsp;ينصح بمحاولة تناول الدواء في نفس الوقت من كل اليوم. سيساعد ذلك في تذكر تناول الدواء.</p><p dir="RTL">&nbsp;جارديا 16 ملغم، 32 ملغم: يمكن تقسيم القرص إلى جرعات متساوية.</p><p dir="RTL">&nbsp;ارتفاع ضغط الدم:</p><p dir="RTL">&nbsp;&bull; الجرعة الموصى بها هي 8 ملغم تؤخذ مرة في اليوم. قد يقوم الطبيب بزيادة&nbsp; الجرعة إلى 16 ملغم تؤخذ مرة في اليوم وقد يزيدها أكثر من ذلك إلى 32 ملغم مرة في اليوم، وذلك بناء على استجابة ضغط الدم لديك.</p><p dir="RTL">&nbsp;في بعض المرضى؛ مثل أولئك الذين يعانون من مشاكل في الكبد أو الكلية أو الذين فقدوا مؤخرا بعض سوائل الجسم على سبيل المثال عبر القيء أو الإسهال أو عبر تناول أدوية مدرة للبول، حينها سيصف لك الطبيب جرعة ابتدائية أقل.</p><p dir="RTL">&nbsp;يمكن أن تكون الاستجابة لهذا النوع من الدواء أقل عن المعتاد في المرضى أصحاب البشرة السوداء، إذا ما كان هذا الدواء هو الوسيلة الوحيدة المستخدمة للعلاج، لذلك قد يحتاج هؤلاء المرضى إلى زيادة الجرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;استخدام الدواء مع الأطفال والمراهقين الذين يعانون من ارتفاع ضغط الدم:</strong></p><p dir="RTL">&nbsp;الأطفال من سن 6 إلى أقل من 18 سنة:</p><p dir="RTL">&nbsp;الجرعة الأولية الموصى بها هي 4 ملغم تؤخذ مرة في اليوم.</p><p dir="RTL">&nbsp;في حالات المرضى الذين وزنهم أقل من 50 كجم: في بعض المرضى الذين لا يتم التحكم في ضغط الدم لديهم بشكل كاف، قد يقرر الطبيب زيادة الجرعة إلى 8 ملغم كحد أقصى، تؤخذ مرة في اليوم.</p><p dir="RTL">&nbsp;في حالات المرضى الذين وزنهم 50 كجم أو أكثر: في بعض المرضى الذين لا يتم التحكم في ضغط الدم لديهم بشكل كاف، قد يقرر الطبيب زيادة الجرعة إلى 8 ملغم أو 16 ملغم، تؤخذ مرة في اليوم.</p><p dir="RTL">&nbsp;فشل القلب في المرضى البالغين:</p><p dir="RTL">&nbsp;&bull; الجرعة الابتدائية / الأولية الموصى بها هي 4 ملغم تؤخذ مرة في اليوم. يمكن أن يرفع الطبيب جرعتك من الدواء عبر مضاعفة الجرعة على فترة زمنية لا تقل عن أسبوعين وحتى جرعة تصل إلى 32 ملغم، تؤخذ مرة في اليوم. يمكن تناول دواء جارديا مع أدوية أخرى لعلاج فشل القلب، سيقرر الطبيب أي من الأدوية يناسبك.</p><p dir="RTL"><strong>&nbsp;إذا تناولت جرعات من دواء جارديا أكثر من الموصى بها:</strong></p><p dir="RTL">&nbsp;يجب استشارة الطبيب أو الصيدلي على الفور إذا تناولت جرعة أكثر من الموصى بها من هذا الدواء.</p><p dir="RTL"><strong>&nbsp;إذا نسيت تناول الدواء</strong></p><p dir="RTL">&nbsp;لا تتناول جرعة مزدوجة لتعويض جرعتك الفائتة. فقط قم بتناول الجرعة التالية كما المعتاد.</p><p dir="RTL"><strong>&nbsp;إذا توقفت عن تناول الدواء</strong></p><p dir="RTL">&nbsp;إذا توقفت عن تناول جارديا فإن ضغط الدم قد يزداد مرة أخرى. لذلك لا تقم أبدا بإيقاف هذا الدواء قبل التحدث مع الطبيب.</p><p dir="RTL">&nbsp;يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى. من الضروري أن تكون على دراية بهذه الأعراض الجانبية.</p><p dir="RTL"><strong>&nbsp;يجب التوقف الفوري عن تناول هذا الدواء، مع سرعة التوجه إلى المستشفى إذا عانيت من أي من أعراض الحساسية الآتية: </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس، مع أو بدون تورم في الوجه أو الشفاه أو اللسان و / أو الحلق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه أو الشفاه أو اللسان و / أو الحلق، مما قد يسبب مشاكل في البلع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور الشديد بالحكة في الجلد (كتل مرتفعة).</p><p dir="RTL">&nbsp;يمكن أن يتسبب هذا الدواء في نقص عدد كرات الدم البيضاء. قد تتأثر سلبا مقاومة الجسم للعدوى، كما يمكن أن تلاحظ شعور بالتعب أو العدوى أو ارتفاع في درجة الحرارة.&nbsp; يجب استشارة الطبيب في الحال إذا حدث ذلك. سيقوم الطبيب بإجراء فحوصات للدم في بعض الأحيان من أجل التأكد إذا كان لهذا الدواء أي تأثير على الدم (نقص الخلايا المحببة).</p><p dir="RTL">&nbsp;تشمل الأعراض الجانبية المحتملة الأخرى على الآتي:</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية المألوفة (تؤثر في 1 إلى 10 من بين 100 شخص):</strong></p><p dir="RTL">&nbsp;الشعور بالدوار.</p><p dir="RTL">&nbsp;صداع</p><p dir="RTL">&nbsp;عدوى الجهاز التنفسي</p><p dir="RTL">&nbsp;انخفاض ضغط الدم يمكن أن يتسبب في الشعور بالإغماء أو الدوار.</p><p dir="RTL">&nbsp;تغيرات في نتائج فحوصات الدم:</p><p dir="RTL">&nbsp;زيادة نسبة البوتاسيوم في الدم، خاصة إذا كنت تعاني بالفعل من مشاكل في الكلية أو فشل في القلب. إذا كانت هذه الزيادة كثيرة، فقد تلاحظ شعور بالتعب أو الضعف أو عدم انتظام في ضربات القلب أو إحساس بوخز الإبر.</p><p dir="RTL">&nbsp;تأثيرات على وظائف وطريقة عمل الكلية، خاصة إذا كنت تعاني بالفعل من مشاكل في الكلية أو فشل في القلب. في بعض الحالات النادرة؛ يمكن أن يحدث فشل كلوي.</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية النادرة جدا (تؤثر في أقل من 1 من بين 10,000 شخص):</strong></p><p dir="RTL">&nbsp;تورم في الوجه أو الشفاه أو اللسان و / أو الحلق.</p><p dir="RTL">&nbsp;نقص عدد خلايا الدم الحمراء أو البيضاء. يمكن أن تلاحظ شعور بالتعب أو العدوى أو ارتفاع في درجة الحرارة.</p><p dir="RTL">&nbsp;الطفح الجلدي، طفح جلدي مرتفع (شرى).</p><p dir="RTL">&nbsp;الشعور بالحكة</p><p dir="RTL">&nbsp;ألم الظهر، ألم في المفاصل والعضلات.</p><p dir="RTL">&nbsp;تغيرات في وظائف وطريقة عمل الكبد، بما في ذلك التهاب التهاب في الكبد.&nbsp; قد تلاحظ الإصابة بالتعب أو اصفرار الجلد وبياض العينين وأعراضا مشابهة لأعراض الانلفونزا.</p><p dir="RTL">&nbsp;سعال.</p><p dir="RTL">&nbsp;غثيان</p><p dir="RTL">&nbsp;تغيرات في نتائج فحوصات الدم:</p><p dir="RTL">&nbsp;نقص مستوى الصوديوم في الدم. إذا كان هذا النقص كبير، فد تلاحظ شعور بالإرهاق أو فقدان الطاقة أو تقلصات في العضلات.</p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية غير المعروفة( لا يمكن تحديد نسبة تكرار الأعراض من البيانات المتاحة):</strong></p><p dir="RTL">&nbsp;إسهال</p><p dir="RTL">&nbsp;تبدو الأعراض الجانبية الناتجة عن تناول هذا الدواء في الأطفال الذين يعالجون من ارتفاع ضغط الدم مشابهة لتلك الأعراض الجانبية في المرضى البالغين، ولكنها تحدث في كثير من الأحيان. يعد التهاب الحلق من أشهر الأعراض الجانبية في الأطفال. يعد أيضا سيلان الأنف، ارتفاع درجة الحرارة، زيادة معدل ضربات القلب من الأعراض الجانبية المألوفة في الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&bull; يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">&nbsp;&bull; لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضحة على شريط الأقراص وعلى العبوة بعد كلمة (EXP). يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">&nbsp;&bull; يجب عدم التخزين في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&nbsp;لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية. وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة: كانديزارتان سيلكيزيتيل يحتوي كل قرص على 8 ملغم أو 16 ملغم من كانديزارتان سيلكيزيتيل.</p><p dir="RTL">&nbsp;باقي المكونات: هيدروكسي بروبيل سيليلوز، لاكتوز مونوهيدرات، بولي ايثيلين غليكول، نشا الذرة، اوكسيد الحديد، كربوكسي ميثيل السليلوز الكالسيوم، والمغنيسيوم الإستارات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جارديا 8ملغم أقراص: &nbsp;أقراص زهرية منقطة مستديرة منقوشة برمز 72واحد وعادي من الجهة الأخرى.</p><p dir="RTL">جارديا 16 ملغم أقراص: أقراص زهرية منقطة مستديرة منقوشة برمز 71جانب واحد ،و خط للقسم على الجانب الآخر. على جانب E</p><p dir="RTL">أقراص جارديا معبأة في أشرطة من الألومنيوم مطوية في علبة كرتون مع نشرة ,PVC/ PVDC/ ، في عبوات حجم 30 قرص.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">المتحدة للصناعات الدوائية- الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Jun-19
SPM190326

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gardia 8 mg Tablets.
Gardia 16 mg Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 8 mg candesartan cilexetil.
Each tablet contains 39.5 mg lactose monohydrate.
Each tablet contains 16 mg candesartan cilexetil.
Each tablet contains 79 mg lactose monohydrate.
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
Gardia 8mg Tablets: Faint pink mottled rounded biconvex tablet embossed with E72 on one side plain on the other.
The tablet can be divided into equal doses
Gardia 16mg Tablets: Faint pink mottled round scored biconvex tablet embossed with E71 on one side, plain on the other side.
The tablet can be divided into equal doses

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gardia is indicated for the:</p><p>&bull; Treatment of essential hypertension in adults.</p><p>&bull; Treatment of hypertension in children and adolescents aged 6 to &lt;18 years.</p><p>&bull; Treatment of adult patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction &le; 40%) when Angiotensin Converting Enzyme (ACE) inhibitors are not tolerated or as add-on therapy to ACE inhibitors in patients with symptomatic heart failure, despite optimal therapy, when mineralocorticoid receptor antagonists are not tolerated (see sections 4.2, 4.4, 4.5, and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology in Hypertension</u></p><p>The recommended initial dose and usual maintenance dose of Gardia is 8 mg once daily. Most of the antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16 mg once daily and to a maximum of 32 mg once daily. Therapy should be adjusted according to blood pressure response.</p><p>Gardia may also be administered with other antihypertensive agents &ndash; (see sections 4.3, 4.4, 4.5 and 5.1). Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Gardia.</p><p><em>Older people</em></p><p>No initial dose adjustment is necessary in elderly patients.</p><p><em>Patients with intravascular volume depletion</em></p><p>An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see section 4.4).</p><p><em>Patients with renal impairment</em></p><p>The starting dose is 4 mg in patients with renal impairment, including patients on haemodialysis. The dose should be titrated according to response. There is limited experience in patients with very severe or end-stage renal impairment (Cl<sub>creatinine</sub>&nbsp;&lt; 15 ml/min) (see section 4.4).</p><p><em>Patients with hepatic impairment</em></p><p>An initial dose of 4 mg once daily is recommended in patients with mild to moderate hepatic impairment. The dose may be adjusted according to response. Gardia is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3 and 5.2).</p><p><em>Black patients</em></p><p>The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients. Consequently, uptitration of Gardia and concomitant therapy may be more frequently needed for blood pressure control in black patients than in non-black patients (see section 5.1).</p><p><em>Paediatric Population</em></p><p><em>Children and adolescents aged 6 to &lt;18 years:</em></p><p>The recommended starting dose is 4 mg once daily.</p><p>&bull; For patients weighing &lt; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to a maximum of 8 mg once daily.</p><p>&bull; For patients weighing &ge; 50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to 8 mg once daily and then to 16 mg once daily if needed (see section 5.1).</p><p>Doses above 32 mg have not been studied in paediatric patients.</p><p>Most of the antihypertensive effect is attained within 4 weeks.</p><p>For children with possible intravascular volume depletion (e.g., patients treated with diuretics, particularly those with impaired renal function), Gardia treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered (see section 4.4).</p><p>Gardia has not been studied in children with glomerular filtration rate less than 30 ml/min/1.73m<sup>2</sup>&nbsp;(see section 4.4).</p><p><em>Black paediatric patients</em></p><p>The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients (see section 5.1).</p><p><em>Children aged below 1 year to &lt;6 years</em></p><p>The safety and efficacy in children aged 1 to &lt;6 years of age has not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>Gardia is contraindicated in children aged below 1 year (see section 4.3).</p><p><u>Posology in Heart Failure</u></p><p>The usual recommended initial dose of Gardia is 4 mg once daily. Up-titration to the target dose of 32 mg once daily (maximum dose) or the highest tolerated dose is done by doubling the dose at intervals of at least 2 weeks (see section 4.4). Evaluation of patients with heart failure should always comprise assessment of renal function including monitoring of serum creatinine and potassium. Gardia can be administered with other heart failure treatment, including ACE inhibitors, beta-blockers, diuretics and digitalis or a combination of these medicinal products. Gardia may be co-administered with an ACE-inhibitor in patients with symptomatic heart failure despite optimal standard heart failure therapy when mineralocorticoid receptor antagonists are not tolerated.. The combination of an ACE inhibitor, a potassium-sparing diuretic (e.g. spironolactone) and Gardia is not recommended and should be considered only after careful evaluation of the potential benefits and risks (see sections 4.4, 4.8 and 5.1).</p><p><em>Special patient populations</em></p><p>No initial dose adjustment is necessary for elderly patients or in patients with intravascular volume depletion or renal impairment or mild to moderate hepatic impairment.</p><p><em><u>Paediatric Population</u></em></p><p>The safety and efficacy of Gardia in children aged between birth and 18 years have not been established in the treatment of heart failure. No data are available.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>Gardia should be taken once daily with or without food.</p><p>The bioavailability of candesartan is not affected by food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to candesartan cilexetil or to any of the excipients listed in section 6.1.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
Severe hepatic impairment and/or cholestasis.
Children aged below 1 year (see section 5.3).
The concomitant use of Gardia with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR< 60ml/min/1.73m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p>There is evidence that the concomitant use of ACE inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see Section 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em><u>Renal impairment</u></em></p><p>As with other agents inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible patients treated with Gardia.</p><p>When Gardia is used in hypertensive patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is limited experience in patients with very severe or end-stage renal impairment (Cl<sub>creatinine</sub>&nbsp;&lt; 15 ml/min). In these patients Gardia should be carefully titrated with thorough monitoring of blood pressure.</p><p>Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of Gardia, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine &gt; 265 &mu;mol/l (&gt; 3 mg/dl).</p><p><em><u>Use in paediatric patients including patients with renal impairment</u></em></p><p>Gardia has not been studied in children with a glomerular filtration rate less than 30 ml/min/1.73m<sup>2</sup>&nbsp;(see section 4.2).</p><p><em><u>Concomitant therapy with an ACE inhibitor in heart failure</u></em></p><p>The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may increase when Gardia is used in combination with an ACE inhibitor (see section 4.8). Triple combination of an ACE-inhibitor, a mineralocorticoid receptor antagonist and candesartan cilexetil is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em><u>Haemodialysis</u></em></p><p>During dialysis the blood pressure may be particularly sensitive to AT<sub>1</sub>-receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, Gardia should be carefully titrated with thorough monitoring of blood pressure in patients on haemodialysis.</p><p><em><u>Renal artery stenosis</u></em></p><p>Medicinal products that affect the renin-angiotensin-aldosterone system, including angiotensin II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.</p><p><em><u>Kidney transplantation</u></em></p><p>There is no experience regarding the administration of Gardia in patients with a recent kidney transplantation.</p><p>&nbsp;</p><p><em><u>Hypotension</u></em></p><p>Hypotension may occur during treatment with Gardia in heart failure patients. It may also occur in hypertensive patients with intravascular volume depletion such as those receiving high dose diuretics. Caution should be observed when initiating therapy and correction of hypovolemia should be attempted.</p><p>For children with possible intravascular volume depletion (e.g. patients treated with diuretics, particularly those with impaired renal function), candesartan treatment should be initiated under close medical supervision and a lower starting dose should be considered (see section 4.2).</p><p><em><u>Anaesthesia and surgery</u></em></p><p>Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p><p><em><u>Aortic and mitral valve stenosis (obstructive hypertrophic cardiomyopathy)</u></em></p><p>As with other vasodilators, special caution is indicated in patients suffering from haemodynamically relevant aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><em><u>Primary hyperaldosteronism</u></em></p><p>Patients with primary hyperaldosteronism will not generally respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin-aldosterone system. Therefore, the use of Gardia is not recommended in this population.</p><p><em><u>Hyperkalaemia</u></em></p><p>Concomitant use of Gardia with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products that may increase potassium levels (e.g. heparin) may lead to increases in serum potassium in hypertensive patients. Monitoring of potassium should be undertaken as appropriate.</p><p>In heart failure patients treated with Gardia, hyperkalaemia may occur. Periodic monitoring of serum potassium is recommended. The combination of an ACE inhibitor, a potassium-sparing diuretic (e.g. spironolactone) and Gardia is not recommended and should be considered only after careful evaluation of the potential benefits and risks.</p><p><em><u>General</u></em></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with other medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be excluded with AIIRAs. As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke.</p><p>The antihypertensive effect of candesartan may be enhanced by other medicinal products with blood pressure lowering properties, whether prescribed as an antihypertensive or prescribed for other indications.</p><p>Gardia contains lactose. Patients with rare hereditary problems of galactose intolerancetotal lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p><em><u>Pregnancy</u></em></p><p>AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>In post-menarche patients the possibility of pregnancy should be evaluated on a regular basis. Appropriate information should be given and/or action taken to prevent the risk of exposure during pregnancy (see sections 4.3 and 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine and enalapril. No clinically significant pharmacokinetic interactions with these medicinal products have been identified.</p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of potassium should be undertaken as appropriate (see section 4.4).</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. A similar effect may occur with AIIRAs. Use of candesartan with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p>As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><em><u>Paediatric population</u></em></p><p>Interaction studies have only been performed in adults</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</p></td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em><u>Breastfeeding</u></em></p><p>Because no information is available regarding the use of Gardia during breastfeeding, Gardia is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of candesartan on the ability to drive and use machines have been performed. However, it should be taken into account that occasionally dizziness or weariness may occur during treatment with Gardia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Treatment of Hypertension</u></em></p><p>In controlled clinical studies adverse reactions were mild and transient. The overall incidence of adverse events showed no association with dose or age. Withdrawals from treatment due to adverse events were similar with candesartan cilexetil (3.1%) and placebo (3.2%).</p><p>In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo. By this definition, the most commonly reported adverse reactions were dizziness/vertigo, headache and respiratory infection.</p><p>The table below presents adverse reactions from clinical trials and post-marketing experience.</p><p>The frequencies used in the tables throughout section 4.8 are: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Respiratory infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperkalaemia, hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness/vertigo, headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Increased liver enzymes, abnormal hepatic function or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure in susceptible patients (see section 4.4)</p></td></tr></tbody></table><p><em>Laboratory findings</em></p><p>In general, there were no clinically important influences of Gardia on routine laboratory variables. As for other inhibitors of the renin-angiotensin-aldosterone system, small decreases in haemoglobin have been seen. No routine monitoring of laboratory variables is usually necessary for patients receiving Gardia. However, in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.</p><p><em>Paediatric population</em></p><p>The safety of candesartan cilexetil was monitored in 255 hypertensive children and adolescents, aged 6 to &lt;18 years old, during a 4 week clinical efficacy study and a 1 year open label study (see section 5.1). In nearly all different system organ classes, the frequency of adverse events in children are within common/uncommon range. Whilst the nature and severity of the adverse events are similar to those in adults (see the table above), the frequency of all adverse events are higher in children and adolescent, particularly in:</p><p>&bull; Headache, dizziness and upper respiratory tract infection, are &ldquo;very common&rdquo; (ie, &ge;1/10) in children and common (&ge; 1/100 to &lt; 1/10) in adults.</p><p>&bull; Cough is &ldquo;very common&rdquo; (ie, &gt; 1/10) in children and very rare (&lt;1/10,000) in adults.</p><p>&bull; Rash is &ldquo;common&rdquo; (ie, &ge;1/100 to &lt;1/10) in children and &ldquo;very rare&rdquo; (&lt;1/10,000) in adults.</p><p>&bull; Hyperkalemia, hyponatraemia and abnormal liver function are uncommon (&ge; 1/1,000 to &lt; 1/100) in children and very rare (&lt; 1/10,000) in adults.</p><p>&bull; Sinus arrhythmia, Nasopharyngitis, pyrexia are &ldquo;common&rdquo; (ie, &ge;1/100 to &lt;1/10) and oropharyngeal pain is &ldquo;very common&rdquo; (ie, &ge;1/10) in children; but none are reported in adults. However these are temporary and widespread childhood illnesses.</p><p>The overall safety profile for candesartan cilexetil in paediatric patients does not differ significantly from the safety profile in adults.</p><p><em><u>Treatment of Heart Failure</u></em></p><p>The adverse experience profile of Gardia in adult heart failure patients was consistent with the pharmacology of the drug and the health status of the patients. In the CHARM clinical programme, comparing Gardia in doses up to 32 mg (n=3,803) to placebo (n=3,796), 21.0% of the candesartan cilexetil group and 16.1% of the placebo group discontinued treatment because of adverse events. The most commonly reported adverse reactions were hyperkalaemia, hypotension and renal impairment. These events were more common in patients over 70 years of age, diabetics, or subjects who received other medicinal products which affect the renin-angiotensin-aldosterone system, in particular an ACE inhibitor and/or spironolactone.</p><p>The table below presents adverse reactions from clinical trials and post-marketing experience.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and agranulocytosis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Dizziness, headache</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Increased liver enzymes, abnormal hepatic function or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal impairment, including renal failure in susceptible patients (see section 4.4)</p></td></tr></tbody></table><p><em>Laboratory findings</em></p><p>Hyperkalaemia and renal impairment are common in patients treated with Gardia for the indication of heart failure. Periodic monitoring of serum creatinine and potassium is recommended (see section 4.4).</p><p><u>&nbsp;</u></p><p><strong>e. To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>- The National Pharmacovigilance and Drug Safety Centre (NPC) :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Symptoms</u></em></p><p>Based on pharmacological considerations, the main manifestation of an overdose is likely to be symptomatic hypotension and dizziness. In individual case reports of overdose (of up to 672 mg candesartan cilexetil) in an adult, patient recovery was uneventful.</p><p><em><u>Management</u></em></p><p>If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, isotonic saline solution. Sympathomimetic medicinal products may be administered if the above-mentioned measures are not sufficient.</p><p>Candesartan is not removed by haemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacotherapeutic group:</em></p><p>Angiotensin II antagonists, plain, ATC code: C09CA06</p><p><em>Mechanism of action</em></p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension, heart failure and other cardiovascular disorders. It also has a role in the pathogenesis of end organ hypertrophy and damage. The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT<sub>1</sub>) receptor.</p><p><em>Pharmacodynamic effects</em></p><p>Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active substance, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an AIIRA, selective for AT<sub>1</sub>&nbsp;receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity.</p><p>Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin. There is no effect on ACE and no potentiation of bradykinin or substance P. In controlled clinical trials comparing candesartan with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. The antagonism of the angiotensin II (AT<sub>1</sub>) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.</p><p><em>Clinical efficacy and safety</em></p><p><em><u>Hypertension</u></em></p><p>In hypertension, candesartan causes a dose-dependent, long-lasting reduction in arterial blood pressure. The antihypertensive action is due to decreased systemic peripheral resistance, without reflex increase in heart rate. There is no indication of serious or exaggerated first dose hypotension or rebound effect after cessation of treatment.</p><p>After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs within 2 hours. With continuous treatment, most of the reduction in blood pressure with any dose is generally attained within four weeks and is sustained during long-term treatment. According to a meta-analysis, the average additional effect of a dose increase from 16 mg to 32 mg once daily was small. Taking into account the inter-individual variability, a more than average effect can be expected in some patients. Candesartan cilexetil once daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between maximum and trough effects during the dosing interval. The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients with mild to moderate hypertension. The trough blood pressure reduction (systolic/diastolic) was 13.1/10.5 mmHg with candesartan cilexetil 32 mg once daily and 10.0/8.7 mmHg with losartan potassium 100 mg once daily (difference in blood pressure reduction 3.1/1.8 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive. An increased antihypertensive effect is also seen when candesartan cilexetil is combined with amlodipine or felodipine.</p><p>Medicinal products that block the renin-angiotensin-aldosterone system have less pronounced antihypertensive effect in black patients (usually a low-renin population) than in non-black patients. This is also the case for candesartan. In an open label clinical experience trial in 5,156 patients with diastolic hypertension, the blood pressure reduction during candesartan treatment was significantly less in black than non-black patients (14.4/10.3 mmHg vs 19.0/12.7 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate while renal vascular resistance and filtration fraction are reduced. In a 3-month clinical study in hypertensive patients with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced urinary albumin excretion (albumin/creatinine ratio, mean 30%, 95%CI 15-42%). There is currently no data on the effect of candesartan on the progression to diabetic nephropathy.</p><p>The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg), once daily, on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years; 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on COgnition and Prognosis in the Elderly). Patients received candesartan cilexetil or placebo with other antihypertensive treatment added as needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction). There were 26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk 0.89, 95%CI 0.75 to 1.06, p=0.19).</p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><em>Paediatric population - hypertension</em></p><p>The antihypertensive effects of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6 to &lt;17 years in two randomised, double-blind multicentre, 4 week dose ranging studies.</p><p>In children aged 1 to &lt;6 years, 93 patients, 74% of whom had renal disease, were randomised to receive an oral dose of candesartan cilexetil suspension 0.05, 0.20 or 0.40 mg/kg once daily. The primary method of analysis was slope of the change in systolic blood pressure (SBP) as a function of dose. SBP and diastolic blood pressure (DBP) decreased 6.0/5.2 to 12.0/11.1 mmHg from baseline across the three doses of candesartan cilexetil. However, since there was no placebo group, the true magnitude of blood pressure effect remains uncertain which makes a conclusive assessment of benefit-risk balance difficult in this age group.</p><p>In children aged 6 to &lt;17 years, 240 patients were randomised to receive either placebo or low, medium, or high doses of candesartan cilexetil in a ratio of 1: 2: 2: 2. For children who weighed &lt; 50 kg, the doses of candesartan cilexetil were 2, 8, or 16 mg once daily. In children who weighed &gt; 50 kg, the candesartan cilexetil doses were 4, 16 or 32 mg once daily. Candesartan at pooled doses reduced SiSBP by 10.2 mmHg (P&lt; 0.0001) and SiDBP (P=0.0029) by 6.6 mmHg, from the base line. In the placebo group, there was also a reduction of 3.7 mmHg in SiSBP (p=0.0074) and 1.80 mmHg for SiDBP (p=0.0992) from the baseline. Despite the large placebo effect, all individual candesartan doses (and all doses pooled) were significantly superior to placebo. Maximum response in reduction of blood pressure in children below and above 50 kg was reached at 8mg and 16 mg doses, respectively and the effect plateaued after that point. Of those enrolled, 47% were black patients and 29% were female; mean age +/- SD was 12.9 +/- 2.6 years.</p><p>In children aged 6 to &lt; 17 years there was a trend for a lesser effect on blood pressure in black patients compared to non-black patients.</p><p><em><u>Heart Failure</u></em></p><p>Treatment with candesartan cilexetil reduces mortality, reduces hospitalisation due to heart failure, and improves symptoms in patients with left ventricular systolic dysfunction as shown in the Candesartan in Heart failure &ndash; Assessment of Reduction in Mortality and morbidity (CHARM) programme.</p><p>This placebo controlled, double-blind study programme in chronic heart failure (CHF) patients with NYHA functional class II to IV consisted of three separate studies: CHARM-Alternative (n=2,028) in patients with LVEF &le; 40% not treated with an ACE inhibitor because of intolerance (mainly due to cough, 72%), CHARM-Added (n=2,548) in patients with LVEF &le; 40% and treated with an ACE inhibitor, and CHARM-Preserved (n=3,023) in patients with LVEF &gt; 40%. Patients on optimal CHF therapy at baseline were randomised to placebo or candesartan cilexetil (titrated from 4 mg or 8 mg once daily to 32 mg once daily or the highest tolerated dose, mean dose 24 mg) and followed for a median of 37.7 months. After 6 months of treatment 63% of the patients still taking candesartan cilexetil (89%) were at the target dose of 32 mg.</p><p>In CHARM-Alternative, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, hazard ratio (HR) 0.77 (95%CI: 0.67 to 0.89, p&lt; 0.001). This corresponds to a relative risk reduction of 23%. Of candesartan patients 33.0% (95%CI: 30.1 to 36.0) and of placebo patients 40.0% (95%CI: 37.0 to 43.1) experienced this endpoint, absolute difference 7.0% (95%CI: 11.2 to 2.8). Fourteen patients needed to be treated for the duration of the study to prevent one patient from dying of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of all-cause mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.80 (95%CI: 0.70 to 0.92, p=0.001). Of candesartan patients 36.6% (95%CI: 33.7 to 39.7) and of placebo patients 42.7% (95%CI: 39.6 to 45.8) experienced this endpoint, absolute difference 6.0% (95%CI: 10.3 to 1.8). Both the mortality and morbidity (CHF hospitalisation) components of these composite endpoints contributed to the favourable effects of candesartan. Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.008).</p><p>In CHARM-Added, the composite endpoint of cardiovascular mortality or first CHF hospitalisation was significantly reduced with candesartan in comparison with placebo, HR 0.85 (95%CI: 0.75 to 0.96, p=0.011). This corresponds to a relative risk reduction of 15%. Of candesartan patients 37.9% (95%CI: 35.2 to 40.6) and of placebo patients 42.3% (95%CI: 39.6 to 45.1) experienced this endpoint, absolute difference 4.4% (95%CI: 8.2 to 0.6). Twenty-three patients needed to be treated for the duration of the study to prevent one patient from dying of a cardiovascular event or being hospitalised for treatment of heart failure. The composite endpoint of all-cause mortality or first CHF hospitalisation was also significantly reduced with candesartan, HR 0.87 (95%CI: 0.78 to 0.98, p=0.021). Of candesartan patients 42.2% (95%CI: 39.5 to 45.0) and of placebo patients 46.1% (95%CI: 43.4 to 48.9) experienced this endpoint, absolute difference 3.9% (95%CI: 7.8 to 0.1). Both the mortality and morbidity components of these composite endpoints contributed to the favourable effects of candesartan. Treatment with candesartan cilexetil resulted in improved NYHA functional class (p=0.020).</p><p>In CHARM-Preserved, no statistically significant reduction was achieved in the composite endpoint of cardiovascular mortality or first CHF hospitalisation, HR 0.89 (95%CI: 0.77 to 1.03, p=0.118).</p><p>All-cause mortality was not statistically significant when examined separately in each of the three CHARM studies. However, all-cause mortality was also assessed in pooled populations, CHARM-Alternative and CHARM-Added, HR 0.88 (95%CI: 0.79 to 0.98, p=0.018) and all three studies, HR 0.91 (95%CI: 0.83 to 1.00, p=0.055).</p><p>The beneficial effects of candesartan were consistent irrespective of age, gender and concomitant medication. Candesartan was effective also in patients taking both beta-blockers and ACE inhibitors at the same time, and the benefit was obtained whether or not patients were taking ACE inhibitors at the target dose recommended by treatment guidelines.</p><p>In patients with CHF and depressed left ventricular systolic function (left ventricular ejection fraction, LVEF &le; 40%), candesartan decreases systemic vascular resistance and pulmonary capillary wedge pressure, increases plasma renin activity and angiotensin II concentration, and decreases aldosterone levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption and distribution</u></em></p><p>Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The relative bioavailability of the tablet formulation compared with the same oral solution is approximately 34% with very little variability. The estimated absolute bioavailability of the tablet is therefore 14%. The mean peak serum concentration (C<sub>max</sub>) is reached 3to4 hours following tablet intake. The candesartan serum concentrations increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration&nbsp;<em>versus</em>&nbsp;time curve (AUC) of candesartan is not significantly affected by food.</p><p>Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of candesartan is 0.1 l/kg.</p><p>The bioavailability of candesartan is not affected by food.</p><p><em><u>Biotransformation and elimination</u></em></p><p>Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4. Based on&nbsp;<em>in vitro</em>&nbsp;data, no interaction would be expected to occur&nbsp;<em>in vivo</em>&nbsp;with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life of candesartan is approximately 9 hours. There is no accumulation following multiple doses.</p><p>Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about 0.19 ml/min/kg. The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of&nbsp;<sup>14</sup>C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.</p><p><em><u>Pharmacokinetics in special populations</u></em></p><p>In the elderly (over 65 years) C<sub>max</sub>&nbsp;and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects. However, the blood pressure response and the incidence of adverse events are similar after a given dose of Gardia in young and elderly patients (see section 4.2).</p><p>In patients with mild to moderate renal impairment C<sub>max</sub>&nbsp;and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but t<sub>&frac12;</sub>&nbsp;was not altered, compared to patients with normal renal function. The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. The terminal t<sub>&frac12;</sub>&nbsp;of candesartan was approximately doubled in patients with severe renal impairment. The AUC of candesartan in patients undergoing haemodialysis was similar to that in patients with severe renal impairment.</p><p>In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2). There is no experience in patients with severe hepatic impairment.</p><p><em>Paediatric population</em></p><p>The Pharmacokinetic properties of candesartan were evaluated in hypertensive children aged 1 to &lt;6 years and 6 to &lt;17 years in two single dose PK studies.</p><p>In children aged 1 to &lt;6 years, 10 children weighing 10 to &lt;25 kg received a single dose of 0.2 mg/kg, oral suspension. There was no correlation between C<sub>max</sub>&nbsp;and AUC with age or weight. No clearance data has been collected; therefore the possibility of a correlation between clearance and weight/age in this population is unknown.</p><p>In children aged 6 to &lt;17 years, 22 children received a single dose of 16 mg tablet. There was no correlation between C<sub>max</sub>&nbsp;and AUC with age. However weight seems to significantly correlate with C<sub>max</sub>&nbsp;(p=0.012) and AUC (p=0.011). No clearance data, has been collected, therefore the possibility of a correlation between clearance and weight/age in this population is unknown.</p><p>Children &gt;6 years of age had exposure similar to adults given the same dose.</p><p>The pharmacokinetics of candesartan cilexetil have not been investigated in paediatric patients &lt;1 year of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In preclinical safety studies candesartan had effects on the kidneys and on red cell parameters at high doses in mice, rats, dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion. Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells. These changes were considered to be caused by the pharmacological action of candesartan. For therapeutic doses of candesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>In preclinical studies in normotensive neonatal and juvenile rats, candesartan caused a reduction in body weight and heart weight. As in adult animals, these effects are considered to result from the pharmacological action of candesartan. At the lowest dose of 10 mg/kg exposure to candesartan was between 12 and 78 times the levels found in children aged 1 to &lt;6 who received candesartan cilexetil at a dose of 0.2 mg/kg and 7 to 54 times those found in children aged 6 to &lt;17 who received candesartan cilexetil at a dose of 16 mg. As a no observed effect level was not identified in these studies, the safety margin for the effects on heart weight and the clinical relevance of the finding is unknown.</p><p>Foetotoxicity has been observed in late pregnancy (see section 4.6).</p><p>Data from&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;mutagenicity testing indicates that candesartan will not exert mutagenic or clastogenic activities under conditions of clinical use.</p><p>There was no evidence of carcinogenicity.</p><p>The renin-angiotensin-aldosterone system plays a critical role in kidney development&nbsp;<em>in utero.</em>&nbsp;Renin-angiotensin-aldosterone system blockade has been shown to lead to abnormal kidney development in very young mice. Administering drugs that act directly on the renin-angiotensin-aldosterone system can alter normal renal development. Therefore, children aged less than 1 year should not receive Gardia (see section 4.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxypropyl cellulose</p><p>Lactose monohydrate</p><p>Poly Ethylene Glycol</p><p>Magnesium stearate</p><p>Maize starch</p><p>Ferric Iron Oxide</p><p>Calcium Carboxymethyl Cellulose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>GARDIA Tablets are packed in Aluminum foil, PVC coated with PVDC blisters, with a multi folded leaflet packed in registration box.</p><p>Pack sizes:</p><p>30 tablets</p><p>(10 tablets / blister, 3 blisters/ pack).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jun-19
SPC-019-0619-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>